Press Releases - Bristol Myers Squibb
Receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to the full article on the website. Learn how
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Mar 18, 2024 · Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & …
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash ...
Bristol Myers Squibb Announces Leadership Transition Plan
Apr 26, 2023 · NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer ...
Bristol Myers Squibb - Bristol Myers Squibb Reports First Quarter ...
Apr 25, 2024 · Bristol Myers Squibb is executing a strategic productivity initiative that will drive approximately $1.5 billion in cost savings by the end of 2025, the majority of which will be reinvested to fund innovation and drive growth.
Bristol Myers Squibb - Bristol Myers Squibb Showcases the …
Nov 11, 2024 · About the Bristol Myers Squibb-Johnson & Johnson Collaboration. Bristol Myers Squibb and Johnson & Johnson, two unsurpassed leaders in cardiovascular care, are determined to close the gap in unmet needs in thrombosis management by overcoming the …
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s ...
Mar 14, 2024 · U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Corporate news details - Bristol Myers Squibb
Apr 6, 2024 · Bristol Myers Squibb: Delivering Breakthrough Science for Meaningful Interventions in Neuroscience. Neurological conditions represent some of the greatest challenges of our time because of their impact on society, including patients, …
Corporate news details - Bristol Myers Squibb
Jan 23, 2024 · Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb.
Corporate news details - Bristol Myers Squibb
Dec 11, 2023 · SystImmune and Bristol Myers Squibb to co-develop and co-commercialize BL-B01D1 in the United States; SystImmune to retain exclusive rights in Mainland China and Bristol Myers Squibb to gain an exclusive license in the rest of the world